月別アーカイブ: 2013年12月

Grading Pharma In 2013: 16 Drug Companies Ranked

Various pills

Various pills (Photo credit: Wikipedia)

How’d Big Pharma do this year? Very well. I decided to give every drug company with a market capitalization greater than $50 billion a letter grade, just like in school. The basis for the grades: I started with stock performance as a basic metric, and then considered each company’s scientific and medical output, whether or not its behavior was ethical, and the general drift of its business. I skipped the medical device giants, Medtronic and Abbott.

I gave one A+, to Bristol-Myers Squibb, based on its overall performance and its pioneering development of cancer drugs that work by priming the immune system. Gilead Sciences would have gotten one two were it not for the ethical issues surrounding its stopped collaboration with Bristol in hepatitis C, which I think hurt some patients. I am giving no Ds or Fs. There were no big drug disasters on a par with the recall of Merck’s Vioxx or Pfizer’s Bextra this year. Not even close.

Companies are sorted by the letter grade I gave them, and, where there was a tie, by stock performance. Let me know what I got right – and what I got wrong.

The Best Drug Companies

1. Bristol-Myers Squibb Company

Market capitalization: $87 billion
Stock appreciation: +61.4%
Grade: A+

Sure, the big-cap biotechs delivered better stock performance. But Big Pharmas don’t trade like this, and Bristol’s transformation, started under James Cornelius and continuing under current chief Lamberto Andreotti, has simply been amazing. (Former R&D head Elliot Sigal deserves credit, too.) Bristol is leading the way when it comes to cancer immunotherapy, which Science Magazine named as the breakthrough of the year. It’s smartly jettisoning its diabetes business to focus on what is working. And it is a player in hepatitis C, the other hot area this year. The clincher: this company is consistent. Last year was just as good.

2. Celgene Corporation

Market cap: $67 billion
Stock appreciation: +107%
Grade: A

This maker of high-priced cancer drugs delivered incredibly solid performance, even though its medicines didn’t make headlines outside of the biotech sector. Flagship product Revlimid, descended from its initial testing of thalidomide as a cancer drug, is gaining traction as a long-term therapy in multiple myeloma. Abraxane proved effective – and was approved – in pancreatic cancer. And Pomalyst, another thalidomide descendent, was also approved. Investors are becoming excited about apremilast, for psoriasis, too.

3. Biogen Idec

Market Capitalization: $67 billion
Stock appreciation: +92%
Grade: A

The failure of an ALS drug dings Biogen slightly, but it really was a near-perfect year. The launch of MS drug Tecfidera was simply stunning, and Biogen succeeded in getting European protections that will allow it to profit from the medicine there, too. It’s new hemophilia drugs are trucking along.

4. Gilead Sciences

Market capitalization: $113 billion
Stock appreciation: +100%
Grade: A-

Gilead’s purchase of Pharmasset for $11 billion in 2011 is looking like one of the best pharma acquisitions ever. It gave Gilead Sovaldi, a new hepatitis C drug that, as part of a combination pill, could become the new standard of care, helping cure millions of people worldwide from the liver-destroying virus. I would have given Gilead an A+ had it not been for the decision to discontinue a combination of Sovaldi with a Bristol-Myers drug; Gilead’s own combo looks as good in most subtypes of the virus, but not all, and patients now have to wait for an effective combo they might have had earlier if the collaboration had continued. This delay was the best move for Gilead and its shareholders, but not for patients. The worry for investors now: can Sovaldi really be as huge (think $10 billion) as everybody expects?

5. AbbVie

Market capitalization: $86 billion
Stock appreciation: +59%
Grade: A-

AbbVie was supposed to be the less appealing part of Abbott Laboratories, which split itself in two last year. The story was that the pharmaceutical division was dragging down the medical-device-and-baby formula units. But AbbVie has outperformed Abbott for three reasons: its top-seller, Humira for rheumatoid arthritis, continues to perform well; its hepatitis C franchise is the main challenge to Gilead; and its oncology pipeline is delivering.

Trucking Along

6. Roche

Market capitalization: $235 billion
Stock appreciation: +32%
Grade: B+

Roche still seems a bit like two different drug companies. There is Roche, which had saw a major treatment for diabetes and heart disease it had tested in a giant trial fail. And then there is Genentech, which had major drug approvals for Kadcyla, in breast cancer, Perjeta, also in breast cancer, and Gazyva in chronic lymphocytic leukemia. The truth is no company is doing better at developing new cancer drugs. As for the big Swiss drugmaker, well, it’s doing some interesting work in psychiatry.

7. Johnson & Johnson

Market capitalization: $261 billion
Stock appreciation: +32%
Grade: B+

Last year J&J was coping with both with the blaring headlines surrounding the recall of children’s over-the-counter medicines like Tylenol and Motrin and problems with metal-on-metal hip implants. Those problems have abated some, and the pharmaceutical division has been delivering. Xarelto seems to be one of the few new blood thinners not struggling, and Zytiga, for prostate cancer is doing well too.

8. GlaxoSmithKline

Market capitalization: $126 billion
Stock appreciation: 18.1+
Grade: B+

Glaxo had some nice wins at the FDA, bringing to market a combination of drugs for patients with melanoma whose tumors have a particular genetic mutation and new drugs for chronic obstructive pulmonary disease. But it would have won just a B based on the performance of its business. I’m giving it a bump because of Chief Executive Andrew Witty’s attempts at reforming the downside of what it means to be a drug company. After accusations hit that it had bribed doctors in China, Witty decided to stop paying doctors to give talks – the kind of practice that led television personality Dr. Drew Pinsky to hawk a Glaxo antidepressant on radio call-in shows a decade ago. Before that, Glaxo pledged to make the basic data from its clinical trials available to researchers who want it, a big step toward scientific transparency. Maybe Witty’s doing this for show. I wish other drug company CEOs would, too.

9. Amgen

Market capitalization: $85 billion
Stock appreciation: +30.8%
Grade: B

Amgen made a smart purchase, buying Onyx Pharmaceuticals for $10.2 billion in a bid to move into anti-cancer drugs. Other highlights: Good execution on denosumab, for bone cancer and osteoporosis, and solid plans for a business of copycat biotech drugs. There are big hopes for its antibody to PCSK9, which could be the next big cholesterol drug. No reason to jump up and down with excitement, but nothing to frown about, either.

10. Pfizer Inc.

Market capitalization: $199 billion
Stock appreciation: +23%
Grade: B

Pfizer spun off its animal health business, Zoetis, generating investor excitement that the company could complete an even bigger break-up, separating its generic drug business from its pipeline of experimental drugs. The launches of the blood thinner Eliquis, sold with Bristol-Myers Squibb, and Xeljanz, for rheumatoid arthritis, are selling less briskly than many investors hoped. But palbociclib, an experimental breast cancer drug, is looking promising. Trial results from a mid-stage study of palbociclib will emerge in 2014. Also expected: a big trial testing whether its Prevnar 13 vaccine prevents pneumonia in adults.

11. Novartis

Market cap: $189 billion
Stock apprecition: +22.5%
Grade: B

Novartis is a cutting edge oncology company. It is developing the cancer-fighting gene therapy developed by Carl June at the University of Pennsylvania, and that treatment, known as a chimeric antigen receptor immunotherapy. An experimental multiple myeloma drug is also showing promise. Its plan to consider selling off some divisions is smart and shareholder-friendly. What lowered its grade: a research scandal in Japan over studies of Diovan, the blood pressure drug that was its best-seller for years, and lingering questions about manufacturing in its direct-to-consumer business.

The Rear Guard

12. Novo Nordisk

Market capitalization: $75 billion
Stock appreciation: +7.8%
Grade: B-

After years of phenomenal performance as it invaded the U.S. insulin market, Novo was hit by a big setback this year as the FDA told it to conduct more safety trials of a long-acting insulin. Still, the company has a formidable collection of diabetes medicines and is doing fine.

13. Merck & Co.

Market capitalization: $143 billion
Stock appreciation: +19.4%
Grade: B-

Oh, Merck, running so hard to stay in place. This time last year its niacin drug for high cholesterol proved toxic and it delayed filing a key osteoporosis pill with the FDA. Then it announced it was replacing Peter Kim, head of R&D. It later announced that it would cut 8,500 jobs. Next year could be tough, too. The study of Vytorin in heart disease that should read out in 2014 is, to put it kindly, high risk.

No wonder Chief Executive Ken Frazier is having trouble regaining Wall Street’s confidence. But he is doing a lot of the right things: replacing Kim with former Amgen R&D honcho Roger Perlmutter; focusing the labs on a few key programs, including its exciting PD-1 antibody for various cancers, which could be a breakout product; expressing a willingness to spin off animal health or do other shareholder-friendly deals. It’s the sense that Merck is making a real shift that saved it from a lower grade, and that could deliver dividends in the new year.

14. Sanofi

Market capitalization: $135 billion
Stock performance: +7.3%
Grade: B-

Sanofi had a great year last year; this year, not so much. I’d like to see more evidence that the R&D turnaround that chief executive Chris Viehbacher and research chief Elias Zerhouni are trying to execute. Going well: the collaborations with biotech Regeneron, including its experimental cholesterol drug that targets the enzyme PCSK9. Not going well: the company keeps missing Wall Street’s earnings forecasts after promising to return to growth, and, like GlaxoSmithKline, it got embroiled in accusations of Chinese bribery.

15. AstraZeneca

Market capitalization: $73 billion
Stock appreciation: +24.5%
Grade: C+

The market seems happy with the performance of new chief executive Pascal Soriot, but I’m not. He made a big bet on Brilinta, the new blood thinner that is similar to Plavix, and sales have increased 208% – to just $75 million in the third quarter. There’s no indication this will be a big drug, especially when there is a Department of Justice investigation looming over its clinical trials. There doesn’t seem to be much of a strategy to the company’s acquisitions, although its big purchase of its diabetes venture with Bristol-Myers Squibb at least makes sense. The pipeline from its MedImmune division is promising, but there needs to be a clearer sense of direction for the company as a whole.

16. Eli Lilly and Company

Market capitalization: $57 billion
Stock appreciation: +2.4%
Grade: C

Over the past decade, Eli Lilly has ceded its leadership in diabetes to Novo Nordisk and Sanofi. Now, patent protection is vanishing for its stable of neuroscience drugs, most notably Zyprexa (gone) and Cymbalta (going). The diabetes business is resurgent, and there’s been some positive movement in cancer. But it seems like every time anyone gets excited about Lilly’s prospects, it’s over a medicine with very slim prospects: solanezumab for Alheimer’s or ramucirumab in breast cancer. And those potential home runs keep getting turned into strikeouts.

Source Article from http://www.forbes.com/sites/matthewherper/2013/12/31/grading-pharma-in-2013-16-drug-companies-ranked/
Grading Pharma In 2013: 16 Drug Companies Ranked
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results

Frontier Pharma – Rheumatoid Arthritis: Identifying and Commercializing First-in-Class Innovation

ALBANY, New York, December 31, 2013 /PRNewswire/ –

- Market Analysis, Size, Share, Growth, Trends And Forecast Research Report Available Online By ResearchMoz.us

ResearchMoz.us includes new market research report “Frontier Pharma – Rheumatoid Arthritisto its huge collection of research reports.

Summary: Researchmoz presents this most up-to-date research on Frontier Pharma – Rheumatoid Arthritis (http://www.researchmoz.us/frontier-pharma-rheumatoid-arthritis-identifying-and-commercializing-first-in-class-innovation-report.html). Research has released a new pharmaceutical report, “Frontier Pharma: Rheumatoid Arthritis Identifying and Commercializing First-in-Class Innovation”. This highly competitive market is saturated with multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet more of these treatments are expected to enter the market over the next few years. Despite this, the current developmental pipeline is highly innovative beyond these me-too products and incremental innovations and promises a number of first-in-class products across all stages. These new developments are driven by improvements in the understanding of signaling pathways and underlying disease mechanisms of Rheumatoid Arthritis (RA). These highly innovative products are expected to increase the diversity of available products, in terms of mechanism of action over the coming decade and are likely to have a significant impact on the dynamics of the clinical and commercial landscape.

The market is also characterized by high activity in licensing and co-development deals. In particular, there is sustained commercial interest in pipeline biologic therapies with a range of molecular targets. There is also considerable interest in small molecule inhibitors of intracellular kinesis despite their clinical performances not being as well established as biologics or mAbs.


  • The report analyzes the RA pipeline and strategic alliance landscape with particular emphasis on first-in-class programs.
  • A brief introduction to RA, including symptoms, path physiology, and an overview of the pharmacotherapy
  • Highlights of the changing molecular target landscape between marketed and pipeline products with particular focus on innovation
  • A comprehensive review of first-in-class pipeline therapies; the pipeline is analyzed by Phase distribution, molecule type, molecular target, and administration route
  • Identification and assessment of first-in-class molecular targets highlighting early-stage programs with clinical utility that has yet to be evaluated, as well as an in-depth literature review of novel molecular targets
  • Assessment of the licensing and co-development deals for RA therapeutics

Reasons to buy

  • The report will assist business development strategies of companies who wish to develop RA therapies with improved benefits to existing treatments. In addition, this report will be of interest to companies seeking to expand pipeline portfolios through licensing agreements and co-development deals allowing them to 
  • Understand the overall focal shifts in therapeutic molecular targets of RA treatments
  • Identify first-in-class product development and understand the therapeutic and commercial prospects of first-in-class developmental programs based on available animal model data
  • Assess the value of products benchmarked against licensed and co-developed therapeutic programs 
  • Spot first-in-class programs that are potentially available for licensing and co-development deals

Related & Recently Added Reports by Researchmoz.us to its store.

Global and China Syringes Industry 2013 Market Research Report (http://www.researchmoz.us/global-and-china-syringes-industry-2013-market-research-report-report.html  ) The report firstly introduced Syringes basic information included Syringes definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Syringes industry policy and plan, Syringes product specification, manufacturing process, cost structure etc. then statistics Global and China key manufacturers Syringes capacity production cost price profit production value gross margin etc information, and Global and China Syringes capacity production market share supply demand shortage import export consumption etc data statistics, and Syringes 2009-2014 capacity production price cost profit production value gross margin etc information.

Global and China Prefilled Syringes Industry 2013 Market Research Report (http://www.researchmoz.us/global-and-china-prefilled-syringes-industry-2013-market-research-report-report.html  ) The report firstly introduced Prefilled Syringes basic information included Prefilled Syringes definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Prefilled Syringes industry policy and plan, Prefilled Syringes product specification, manufacturing process, cost structure etc. then statistics Global and China key manufacturers Prefilled Syringes capacity production cost price profit production value gross margin etc information, and Global and China Prefilled Syringes capacity production market share supply demand shortage import export consumption etc data statistics, and Prefilled Syringes 2009-2014 capacity production price cost profit production value gross margin etc information.

Global Gynecological Cancers Market 2014-2018 (http://www.researchmoz.us/global-gynecological-cancers-market-2014-2018-report.html ) Analysts forecast the Global Gynecological Cancers market to grow at a CAGR of 12.47 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in prevalence of gynecological cancer. The Global Gynecological Cancers market has also been witnessing the emergence of personalized medicines. However, the increase in use of CAM could pose a challenge to the growth of this market. Global Gynecological Cancers Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gynecological Cancers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Global and China Desensitizer Industry 2013 Market Research Report (http://www.researchmoz.us/global-and-china-desensitizer-industry-2013-market-research-report-report.html ) The report firstly introduced Desensitizer basic information included Desensitizer definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Desensitizer industry policy and plan, Desensitizer product specification, manufacturing process, cost structure etc. then statistics Global and China key manufacturers Desensitizer capacity production cost price profit production value gross margin etc information, and Global and China Desensitizer capacity production market share supply demand shortage import export consumption etc data statistics, and Desensitizer 2009-2014 capacity production price cost profit production value gross margin etc information.

And also listed Desensitizer upstream raw materials  and down stream analysis and Desensitizer marketing channels industry development trend and proposals. In the end, The report introduced Desensitizer new project SWOT analysis Investment feasibility analysis investment return analysis and also give related research conclusions and development trend analysis on China Desensitizer industry. 

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 8

2.1 The Case for Innovation 8

2.1.1 Growing Opportunities for Biologic Products 8

2.1.2 Diversification of Molecular Targets 8

2.1.3 Innovative First-in-class Product Developments Remain Attractive 9

2.1.4 Changes in the Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Niche Indications 9

2.1.5 Sustained Innovation 10

3 Clinical and Commercial Landscape 11

3.1 Disease Overview 11

3.1.1 Disease Symptoms 12

3.1.2 Environmental Factors and Genetic Predisposition 12

3.1.3 Disease Pathophysiology 12

3.1.4 Pharmacotherapy Algorithm 13

3.2 Overview of Marketed Products for Rheumatoid Arthritis 14

3.3 Molecular Type Analysis 15

3.4 Molecular Target Analysis 16

3.4.1 Intracellular Therapeutic Targets 16

3.4.2 Membrane Therapeutic Targets 17

3.4.3 Extracellular Targets 17

3.5 Innovative Products in the RA Market 17

3.6 Efficacy and Safety of Marketed Products 20

3.7 Current Unmet Needs 22

4 Assessment of Pipeline Product Innovation 23

4.1 Rheumatoid Arthritis Pipeline by Molecule Type, Phase and Therapeutic Targets 23

4.2 Frequently Targeted Intracellular Kinases 25

4.2.1 p38 Kinase 25

4.2.2 MAPK 25

4.2.3 JAK 25

4.2.4 Spleen Tyrosine Kinase (Syk) 25

4.3 Frequently Targeted Cytokines and Receptors 26

4.3.1 TNF-α 26

4.3.2 Toll-Like Receptors 26

4.3.3 B Lymphocyte Stimulator 26

4.4 Efficacy and Safety of Pipeline Products 27

4.5 Comparative Distribution of Programs between the RA Market and Pipeline by Therapeutic Target Family 29

4.6 First-in-class Pipeline Programs Targeting Novel Molecule Targets 31

5 First-in-Class Target and Pipeline Program Evaluation 37

5.1 Cytokines and Receptors 37

5.1.1 Pipeline Programs which Target HMGB-1 37

5.1.2 Pipeline Programs which Target IL-10 Receptor 42

5.1.3 Pipeline Programs which Target HSP 60 46

5.1.4 Pipeline Programs which Target Interleukins 15 and 16 49

5.1.5 Pipeline programs which Target Macrophage Migration Inhibitory Factor (MIF) 52

5.2 Integrins 55

5.2.1 Pipeline Programs which Target Cadherin-11 55

5.2.2 Pipeline Programs which Target α1β1 Integrin (Very Late Antigen-1) 56

5.2.3 Pipeline Programs which Target Vascular Adhesion Protein-1 (VAP-1) 58

5.3 Proteases 59

5.3.1 Pipeline Programs which Target Cathepsin S 59

5.4 Nuclear Receptors 61

5.4.1 Pipeline Programs which Target RAR-Related Orphan Receptor (ROR) 61

5.4.2 Pipeline Programs which Target Nuclear Receptor Related 1 Protein 63

5.5 Intracellular Kinases 64

5.5.1 Pipeline Programs which Target Interleukin 1 Receptor Associated Kinase 4 64

5.6 Ion Channels 66

5.6.1 Pipeline Programs which Target Calcium Release Activated Channels 66

5.7 Others 68

5.7.1 Pipeline Programs which Target F1F0 ATP Synthase 68

5.7.2 Pipeline Programs which Target Immunoproteosome Subunit 7 (IMP7) 69

5.8 Conclusion 71

6 Deals and Strategic Consolidations 73

6.1 Licensing Deals 73

6.2 Co-development Deals 86

6.3 First-in-Class Programs which have not been involved in Licensing or Co-Development Deals 98

7 Appendix 99

7.1 Abbreviations 99

7.2 Methodology 102

7.3 References 102

7.4 References for Figures 5 and 8 109

7.5 Contact Us 111

7.6 Disclaimer 112

Explorer More Pharmaceutical Market Research Reports At:  http://www.researchmoz.us/pharmaceutical-market-reports-38.html

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:
90 Sate Street, Suite 700
Albany, NY 12207
Website@ http://www.researchmoz.us/
Blog: http://www.marketandresearch.org/
Blog: http://medicaldevicesmarket.blogspot.com/
Email: sales@researchmoz.us
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Source Article from http://ca.finance.yahoo.com/news/frontier-pharma-rheumatoid-arthritis-identifying-113000956.html
Frontier Pharma – Rheumatoid Arthritis: Identifying and Commercializing First-in-Class Innovation
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results

Innovus Pharmaceuticals, Inc. Acquires Semprae Laboratories, Inc.

LA JOLLA, Calif., Dec. 30, 2013 (GLOBE NEWSWIRE) — Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) www.innovuspharma.com (INNV) today announced that the Company acquired Semprae Laboratories, Inc. (“Semprae”) through a merger and for shares of common stock of Innovus Pharma. Semprae is a New Jersey company founded by women in 2008 with the goal of improving women’s sexual lives. From the beginning, Semprae has been marketing Zestra(TM), the first non-prescription product clinically proven to increase arousal, sensation, pleasure and satisfaction in women. In 2011, Semprae introduced Zestra Glide(TM), an accompanying water based lubricant. Together the two products had gross sales of approximately $1 million in 2013.

Innovus Pharma currently has two products targeting male sexual health including EjectDelay(TM) for premature ejaculation and CIRCUMserum(TM) to help alleviate reduced penile sensitivity

The acquisition of Semprae brings a number of benefits to Innovus Pharma:

  1. Immediate revenue-generating non-prescription products for women’s sexual health. The Company believes that Zestra(TM) is the only non-prescription product shown in published double-blind, placebo-controlled clinical trials in close to 300 women in the U.S. to have a statistical increase in desire, arousal and satisfaction in women with Female Sexual Arousal Disorder (“FSAD”) with minimal side effects; Zestra(TM) is recommended by many gynecologists, urologists and sex therapist due to its clinical efficacy and safety.
  2. Approximately $1 million in new additional annual gross revenues from the sales of these products;
  3. Strong intellectual property protection. Zestra(TM) is protected by patents extending to beyond 2021.
  4. Immediate retail presence in some of the largest U.S. retail chains such as Walmart, Target, K Mart and Drugstore.com and large drug wholesalers such McKesson, Cardinal Health and H.D. Smith;
  5. Over 85,000 retail customers for these two products; and
  6. Institutional venture shareholders, including Quaker Partners, L.P. and Versant Ventures, L.P.

“This acquisition of Semprae moves Innovus Pharma into the commercial revenue-generating stage with needed products in the female sexual health space,” said Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “In addition, it gives Innovus the needed retail infrastructure for distributing the rest of our OTC products in the US. The combination of Semprae’s two products with those of Innovus Pharma creates a company that is clearly an emerging leader in the over the counter male and female sexual health space.”

“The synergy of Innovus Pharma’s products in the male sexual health space including EjectDelay(TM) for premature ejaculation and CIRCUMSerum(TM) to alleviate reduced penile sensitivity, with Semprae’s products which target the female sexuality area including Zestra(TM) for female sexual arousal and Zestra Glide(TM) as a lubricant, uniquely position the Company in the sexual health category for further accelerated growth and expansion,” said Adele C. Oliva, Partner at Quaker Partners, L.P., a Philadelphia life sciences venture fund and one of the two lead venture investors in Semprae.

“The expertise of the Innovus management team, including Dr. Damaj’s past experience and success with other products in this category when he was CEO of Apricus Biosciences, will be very valuable to grow the Semprae products in the U.S. and internationally,” commented Camille Samuels, former Managing Partner and currently Affiliated Director at Versant Ventures, the other lead venture investor in Semprae.

Dr. Damaj added that Innovus Pharma expects to acquire or develop more products to treat male or female sexual health.

About Zestra(TM) and Glide(TM) and Female Sexual Arousal

Zestra(TM) is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in close to 300 women to increase in a statistical significant manner the arousal, desire and satisfaction in FSAD women. The product has been on the U.S . Canadian markets for approximately five years through major retailers such as Walmart, Target and K-Mart and drug wholesalers such as McKesson, Cardinal Health and HD Smith and through online sales. Zestra Glide(TM) is an accompanying water-based lubricant developed and sold by Semprae. For more information visit www.zestra.com

To date, no product has been approved in the U.S. to treat FSAD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSAD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger.

About EjectDelay(TM) and Premature Ejaculation

EjectDelay(TM) is an over-the-counter (“OTC”) U.S. Food and Drug Administration and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for delay of premature ejaculation (“PE”). The drug typically works within minutes of application to the glans of the penis. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes. For more information visit www.ejectdelay.com.

PE is the most common sexual dysfunction reported by men but is still under-diagnosed and under-treated. PE can happen at any age and its prevalence is consistent across all ages. In an article in The Journal of Sexual Medicine in 2007 Sex Med 2007, D.L. Patrick, D. Rowland and M. Rothman state, “Global studies consistently report that 20-30% of men experience PE worldwide. This means that PE is experienced at similar rates across the globe.”

About CIRCUMserumTM and Reduced Penile Sensitivity

Innovus Pharma acquired the ex-U.S. rights to CIRCUMserumTM from Centric Research Institute (CRI) in early 2013. Reduced Penile Sensitivity (“RPS”) refers to the condition of decreased sensation in the penis during sexual activity. Subjects with RPS report difficulty in stimulating the penis, maintaining erection, and/or achieving orgasm. The duration of intercourse is typically prolonged due to delayed orgasm.

Normal ejaculation is quantified and diagnosed by the time it takes a man to ejaculate from penetrating the vagina. Normal men will ejaculate between 4-8 minutes following penetration of the vagina. Loss of sensation in the penis will cause men to ejaculate after longer than 15 minutes and may take up to 30 minutes, with some never being able to ejaculate.

CIRCUMserumTM is an all-natural cream with the active medicinal excipient cinnamon oil (cinnamaldehyde) at 0.75%. CIRCUMserumTM activates the TRPA1 channels, leading to exciting the nociceptive responsive nerve endings to increase penile sensitivity without affecting the thickness of the skin. For more information visit www.circumserum.com.

About Innovus Pharmaceuticals, Inc.

Innovus Pharma, headquartered in La Jolla, California, is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.

For more information, go to www.innovuspharma.com.


Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products, to successfully commercialize or maintain the sales of such products as Zestra(TM) and Zestra GlideTM and to achieve its other development, commercialization and financial objectives and to fully integrate Semprae into the Company. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.

Source Article from http://finance.yahoo.com/news/innovus-pharmaceuticals-inc-acquires-semprae-110000013.html
Innovus Pharmaceuticals, Inc. Acquires Semprae Laboratories, Inc.
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results